POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R ...
Abstract
Authors
R Córdoba T Prawitz T Westley A Sharma V Kapetanakis L Sabatelli